News Release

Boosting immunotherapy in non-responsive cancer cells

Researchers find that only some types of cancer cells respond well to IFN-γ activation, while others don't, which can have implications for cancer immunotherapy

Peer-Reviewed Publication

Indian Institute of Science (IISc)

Avik Chattopadhyay working in the lab


Avik Chattopadhyay working in the lab

view more 

Credit: Nikita Ramteke

Cancer immunotherapy primes a patient's immune system to better find and destroy cancer cells, improving upon the body's natural ability to fight tumours. Contemporary immunotherapy approaches aim to stimulate immune cells called T cells to target tumours. In this process, the production and functioning of a cytokine (a small signalling protein) known as Interferon-gamma (IFN-γ) are essential for the immune system to eliminate tumours effectively. These approaches affect fewer normal cells when compared to chemotherapy or radiation. However, they are either very expensive or less efficient.  

In a new study, researchers at the Indian Institute of Science (IISc) tried to understand how different types of cancer cells respond to IFN-γ activation. They found that only some types of cancer cells respond well to IFN-γ activation, while others don't. They also suggest some approaches that can be used to make these non-responsive cancer cells better respond to immunotherapy. The study was published in Frontiers in Immunology

"IFN-γ is produced by immune cells such as T cells or natural killer cells. It binds to tumours, and induces apoptosis [cell death]," explains Avik Chattopadhyay, first author and PhD student at the Department of Biochemistry, IISc. "Reports in the literature have shown earlier that if there are lower amounts of IFN-γ or defects in its signalling, then the tumours don't respond well to the immunotherapy processes."  

In the current study, when the team first treated cancer cells in the lab with IFN-γ, they found that the colour of the cell growth medium changed to yellow, indicating that the cells were releasing acidic byproducts such as lactic acid. This led the team to dig deeper into the role of these byproducts. They found that the higher amounts of lactic acid produced in the cell culture medium was due to increased glycolysis, a series of chemical reactions that extracts energy from glucose.  

The team found that cancer cell lines derived from the liver and the kidney showed increased production of nitric oxide (NO) and lactic acid upon IFN-γ activation. This, in turn, increased the production of toxic reactive oxygen species (ROS) leading to oxidative damage, which eventually kills the cancer cells.  

However, cancer cell lines derived from the colon and skin did not produce NO or lactic acid even after being treated with IFN-γ, indicating that they might respond poorly to immunotherapy.  

The researchers then tried to see how these non-responsive cancer cells can also be tweaked to produce lactic acid and NO, and therefore respond better to immunotherapy. They tested different ways, including treating the cells with salts like potassium lactate and other molecules. Such mechanisms – especially adding potassium lactate – reduced cancer cell growth drastically even in the initially non-responsive cancer cells. This observation – that lactic acid plays an important role in the cancer cells' response to immunotherapy – was surprising to the researchers as lactic acid is often thought of as a dead-end metabolic product. 

"The study is really a proof-of-concept at this point," says Dipankar Nandi, Professor at the Department of Biochemistry, IISc, and corresponding author of the study. He adds that further experiments need to be carried out in animal models to see if certain compounds targeting metabolism can boost anti-tumour responses to hard-to-treat cancers, in synergy with IFN-γ activation during immunotherapy.  

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.